- Home
- CRGX vs QSI Comparison
CRGX vs QSI Comparison
Compare CRGX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- QSI
- Stock Information
- Founded
- CRGX 2021
- QSI 2013
- Country
- CRGX United States
- QSI United States
- Employees
- CRGX N/A
- QSI N/A
- Industry
- CRGX
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- QSI Health Care
- Exchange
- CRGX Nasdaq
- QSI Nasdaq
- Market Cap
- CRGX 190.0M
- QSI 219.8M
- IPO Year
- CRGX 2023
- QSI N/A
- Fundamental
- Price
- CRGX $4.39
- QSI $1.83
- Analyst Decision
- CRGX Hold
- QSI Strong Buy
- Analyst Count
- CRGX 7
- QSI 3
- Target Price
- CRGX $4.67
- QSI $2.38
- AVG Volume (30 Days)
- CRGX 487.4K
- QSI 8.8M
- Earning Date
- CRGX 08-11-2025
- QSI 08-06-2025
- Dividend Yield
- CRGX N/A
- QSI N/A
- EPS Growth
- CRGX N/A
- QSI N/A
- EPS
- CRGX N/A
- QSI N/A
- Revenue
- CRGX N/A
- QSI $3,443,000.00
- Revenue This Year
- CRGX $57.81
- QSI $77.57
- Revenue Next Year
- CRGX N/A
- QSI $251.34
- P/E Ratio
- CRGX N/A
- QSI N/A
- Revenue Growth
- CRGX N/A
- QSI 167.94
- 52 Week Low
- CRGX $3.00
- QSI $0.61
- 52 Week High
- CRGX $25.45
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- CRGX 54.10
- QSI 50.82
- Support Level
- CRGX $4.09
- QSI $1.87
- Resistance Level
- CRGX $4.51
- QSI $2.18
- Average True Range (ATR)
- CRGX 0.18
- QSI 0.14
- MACD
- CRGX 0.01
- QSI 0.00
- Stochastic Oscillator
- CRGX 63.29
- QSI 43.65
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.